Squibb-Beechnut

Bristol Myers Squibb (BMS) is a global biopharmaceutical leader that traces its origins to the 19th century, with a significant corporate milestone being the 1989 merger between Bristol-Myers and Squibb Corporation (formerly Squibb Beech-Nut). The company is dedicated to discovering and developing innovative medicines in core therapeutic areas including oncology, hematology, immunology, and cardiovascular disease. BMS manages a high-value commercial portfolio featuring blockbuster drugs such as Opdivo and Eliquis, while maintaining a deep clinical pipeline focused on next-generation modalities like CAR-T cell therapies and protein degraders. Through strategic acquisitions of companies like Celgene and MyoKardia, BMS has solidified its position as a pioneer in precision medicine and specialty therapeutics. The company is headquartered in Princeton, New Jersey, and operates a comprehensive global network for research and manufacturing.